535
Participants
Start Date
September 9, 2008
Primary Completion Date
May 17, 2018
Study Completion Date
May 17, 2018
Denosumab
120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Research Site, Vienna
Research Site, Camperdown
Research Site, East Melbourne
Research Site, Woolloongabba
Research Site, Nedlands
Research Site, New York
Research Site, Marseille
Research Site, Bad Saarow
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Milan
Research Site, Greenville
Research Site, Gainesville
Research Site, Bologna
Research Site, Valencia
Research Site, Ann Arbor
Research Site, Minneapolis
Research Site, Lyon
Research Site, Stuttgart
Research Site, Santa Monica
Research Site, Stanford
Research Site, Villejuif
Research Site, Boston
Research Site, Boston
Research Site, Toronto
Research Site, Montreal
Research Site, Leiden
Research Site, Warsaw
Research Site, Warsaw
Research Site, Palma de Mallorca
Research Site, Barcelona
Research Site, Lund
Research Site, Birmingham
Lead Sponsor
Amgen
INDUSTRY